The British Journal of Diabetes, published by the Association of British Clinical Diabetologists, is a premier journal dedicated to advancing the understanding, prevention, and management of diabetes. With an ISSN of 2397-6233, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that address the complexities of diabetes care and research. While currently not available as an open access option, the journal is committed to enhancing the visibility of cutting-edge diabetes research for healthcare professionals and academics. Located in the heart of England, this journal plays a crucial role in bridging the gap between clinical practice and research innovation, making it an essential resource for practitioners, researchers, and students alike. The British Journal of Diabetes is determined to contribute significantly to the global dialogue on diabetes, as it covers a wide spectrum of topics from epidemiology and public health to novel therapeutic strategies and patient management approaches.

ACTA DIABETOLOGICA, published by SPRINGER-VERLAG ITALIA SRL, is a distinguished peer-reviewed journal dedicated to the rapidly evolving fields of endocrinology, diabetes, and metabolism. With an impressive convergence of research from 1991 to 2024, it is recognized for its significant contributions, boasting a Q1 ranking in Internal Medicine and Q2 rankings in Endocrinology categories as of 2023. Its Scopus rankings further highlight its impact, placing it in the 81st percentile in Internal Medicine. The journal serves as a vital platform for professionals and researchers, facilitating the dissemination of innovative findings and fostering a comprehensive understanding of metabolic disorders. Although the journal is not open access, it remains an essential resource, ensuring high visibility and accessibility of critical research to its scholarly audience.

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

The Journal of Diabetes Science and Technology, published by SAGE Publications Inc, is a premier academic journal that spans vital research and innovative advancements in the fields of diabetes management, bioengineering, and biomedical engineering. With an impressive impact factor reflected in its Q1 rankings across multiple categories such as Bioengineering and Internal Medicine as of 2023, this journal serves as an invaluable resource for researchers, healthcare professionals, and students dedicated to understanding and improving diabetes care and treatment. The journal invites contributions that encompass a wide range of scientific discoveries, methodologies, and technological innovations affecting diabetes and metabolism, ensuring a comprehensive platform for the dissemination of pivotal research findings. Although not an open-access journal, it provides highly curated content that reflects the cutting-edge advancements and emerging trends in diabetes science, making it an essential reference point for the scientific community.

DIABETES CARE, published by the American Diabetes Association, is a premier journal dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 1978, this journal has maintained a commitment to disseminating high-quality research, evidenced by its prestigious ranking in the Q1 category across multiple fields including Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, and Internal Medicine. With an impressive impact factor and distinguished Scopus rankings, DIABETES CARE serves as an essential resource for researchers, clinicians, and students alike, facilitating the exchange of knowledge and fostering innovation in diabetes care. Although not an open-access publication, the journal offers various ways to access groundbreaking studies and advancements in the field. This commitment to excellence reflects the journal's vital role in shaping diabetes research and clinical practices globally.

Diabetes Technology & Therapeutics is a leading journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of diabetes management through innovative technologies and therapeutic strategies. With an impressive impact factor and recognized as a Q1 journal in Endocrinology, Diabetes and Metabolism, as well as Medical Laboratory Technology, it occupies a pivotal position in the academic landscape. This esteemed publication features a comprehensive range of articles that cover cutting-edge research, clinical applications, and developments in diabetes care from 1999 to 2024, making it a critical resource for researchers, health professionals, and students alike. The journal is committed to fostering dialogue between disciplines, especially given its strong rankings in various scientific categories including the 98th percentile in Medical Laboratory Technology. By opting for subscription-based access, readers gain insight into the latest innovations that are shaping diabetes technology and treatment paradigms, thereby enhancing patient outcomes and advancing the scientific community's understanding of this complex disease.

Diabetes Epidemiology and Management, published by Elsevier, is an innovative open-access journal that has been addressing the critical issues surrounding diabetes since its inception in 2021. This journal integrates a comprehensive exploration of the epidemiology, prevention, and management of diabetes, making it a pivotal resource within the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine. With a digital presence represented by E-ISSN 2666-9706, it currently holds a commendable position in the academic landscape, categorized in the Q3 quartile for both Endocrinology and Internal Medicine as per the 2023 metrics. The journal aims to enhance understanding and promote research on diabetes, offering authors a platform to share their findings with a global audience. Researchers, professionals, and students alike can benefit from this essential resource, which is dedicated to advancing the knowledge base and improving clinical practices in diabetes management. With open access options since 2021, the journal ensures that vital research is widely accessible, driving innovation and collaboration in the fight against diabetes.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.